Liver Transplantation for Hepatocellular Carcinoma Arising in Non-cirrhotic Liver: a Propensity Score-matched Retrospective Cohort Study of Two National Databases

Completed

• Conditions: Hepatocellular Carcinoma, Non-cirrhotic Liver

• Registration Number: NCT06364839
• Lead Sponsor: Xiao Xu

Brief Summary

Background: Majority of liver transplantation (LT) recipients for hepatocellular carcinoma (HCC) were concomitant with liver cirrhosis, while few researches focusing on recipients without cirrhosis. Here we aim to investigate the prognosis of non-cirrhosis HCC recipients, expecting to provide theoretical basis for further improvement of these patients.

Methods: This retrospective study analyze outcomes between adult HCC recipients arising in non-cirrhotic and cirrhotic liver from two national databases (CLTR and UNOS, January 2015 to December 2020). Based on important variables, 1:2 and 1:1 propensity score matching (PSM) were performed respectively.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-02-20
• Primary Completion: 2024-03-23
• Study Completion: 2024-03-25
• Status Verified: 2024-04
• Study First Submitted: 2024-04-04
• Study First Submitted QC: 2024-04-12
• Last Update Submitted: 2024-04-12
• Study First Posted: 2024-04-15
• Last Update Posted: 2024-04-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• liver transplants, performed from January 2015 to December 2020

Exclusion Criteria

• pediatric LT; LT for non-tumor lesions; LT for other malignant tumors (cholangiocarcinoma, carcinoma of gallbladder, mixed carcinoma, and secondary tumors); re-transplantation or combined liver-kidney transplantation; incomplete laboratory or clinical data; death within 1 week due to post-operative hemorrhage after LT.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The overall survival rate was evaluated by follow-up investigation and outpatient review	1-3 years
Postoperative complications were evaluated by postoperative imaging and serological examination	3 months	Including rejection after liver transplantation, vascular complications, new metabolic diseases and so on
The tumor-free survival rate was evaluated by follow-up investigation and outpatient review	1-3 years

Trial Locations

Locations (1)

Xiao Xu; 🇨🇳 Hangzhou, Zhejiang, China